| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. )*
Zyla Life Sciences
(Name of Issuer)
Common Stock
(Title of Class of Securities)
98986F108
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| x | Rule 13d-1(b) |
| o | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. | |||||
| 1. | Names of Reporting Persons Tekla Capital Management LLC | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | o | ||||
| (b) | o | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Delaware | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 | |||
| 6. | Shared Voting Power 656,921 | ||||
| 7. | Sole Dispositive Power 656,921 | ||||
| 8. | Shared Dispositive Power 0 | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 656,921 | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.0% | ||||
| 12. | Type of Reporting Person (See Instructions) IN | ||||
2
| CUSIP No. | |||||
| 1. | Names of Reporting Persons Daniel R. Omstead | ||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | ||||
| (a) | o | ||||
| (b) | o | ||||
| 3. | SEC Use Only | ||||
| 4. | Citizenship or Place of Organization Delaware | ||||
| Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 | |||
| 6. | Shared Voting Power 656,921 | ||||
| 7. | Sole Dispositive Power 656,921 | ||||
| 8. | Shared Dispositive Power 0 | ||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 656,921 | ||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | ||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.0% | ||||
| 12. | Type of Reporting Person (See Instructions) IN | ||||
3
| Item 1. | |||
| (a) | Name of Issuer Zyla Life Sciences | ||
| (b) | Address of Issuer’s Principal Executive Offices 600 Lee Road, Suite 100, Wayne, PA 19087 | ||
| Item 2. | |||
| (a) | Name of Person Filing Tekla Capital Management LLC | ||
| (b) | Address of Principal Business Office or, if none, Residence 100 Federal Street, 19th Floor, Boston, MA 02110 | ||
| (c) | Citizenship Delaware Corporation | ||
| (d) | Title of Class of Securities Common Stock | ||
| (e) | CUSIP Number 98986F108 | ||
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | ||
| (a) | o | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |
| (b) | o | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |
| (c) | o | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |
| (d) | o | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | |
| (e) | x | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
| (f) | o | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
| (g) | o | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | |
| (h) | o | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| (i) | o | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | o | A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J); | |
| (k) | o | Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________ | |
4
| Item 4. | Ownership | ||
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |||
| (a) | Amount beneficially owned: 656,921 | ||
| (b) | Percent of class: 7.0% | ||
| (c) | Number of shares as to which the person has: | ||
| (i) | Sole power to vote or to direct the vote 0 | ||
| (ii) | Shared power to vote or to direct the vote 656,921 | ||
| (iii) | Sole power to dispose or to direct the disposition of 656,921 | ||
| (iv) | Shared power to dispose or to direct the disposition of 0 | ||
| Item 5. | Ownership of Five Percent or Less of a Class | ||
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o. | |||
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person | ||
| One person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Zyla Life Sciences. The interest of Tekla Healthcare Opportunities Fund, an investment company registered under the Investment Company Act of 1940, in the Common Stock of Zyla Life Sciences amounted to 656,921 shares or 7.0% of the total outstanding Common Stock at December 31, 2019. | |||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person | ||
| See attached Exhibit A. | |||
| Item 8. | Identification and Classification of Members of the Group | ||
| Not applicable. | |||
| Item 9. | Notice of Dissolution of Group | ||
| N/A | |||
5
| Item 10. | Certification |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. | |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| January 24, 2020 | |
| Date | |
/s/ Laura Woodward | |
| Signature | |
Laura Woodward, Treasurer | |
| Name/Title |
6
Exhibit A
Tekla Capital Management LLC (“TCM”), an investment adviser registered pursuant to Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 656,921 shares (or 7.0%) of the Common Stock of Zyla Life Sciences. (the “Company”) as a result of acting as investment adviser to Tekla Healthcare Opportunities Fund (“THQ”), which is registered as an investment company pursuant to Section 8 of the Investment Company Act of 1940. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the 656,921 shares beneficially owned by THQ. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote of the shares beneficially owned by THQ, which power resides in the fund’s Board of Trustees. TCM carries out the voting of the shares under written guidelines established by the fund’s Board of Trustees.
Exhibit 99.1
Joint Filing Agreement
The undersigned persons, on January 24, 2020, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the Common Stock of Zyla Life Sciences on December 31, 2019.
| Tekla Capital Management LLC | |||
| By | /s/ Laura Woodward | ||
| Laura Woodward | |||
| Daniel R. Omstead | |||
| By | /s/ Daniel R. Omstead | ||
| Daniel R. Omstead | |||